Multiple Ascending Dose Phase 1 Study of ALA-3000
This study evaluated the safety and effectiveness of ALA-3000 for people with depression.
Understand this study
What did researchers investigate?
This study evaluated the safety and effectiveness of ALA-3000 for people with depression.
Who was this study for?
This study was for people with depression. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
- Listed locations
- Little Rock and 3 more locationsSee all locations and recruitment
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
Study information
- Recruitment status
- Completed
- Enrollment listed in the registry
- 37
- Sponsor
- Alar Pharmaceuticals Inc.
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
- Locations
- United States
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT06965569
- Official title
Show the full official title
A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Study of ALA-3000, Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy in Subjects With Treatment-Resistant Depression (TRD)
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
Little Rock · St Louis · Eatontown
1 more locations
- North Canton
Interested in joining this study?
Questions about this study
What did researchers investigate?
This study evaluated the safety and effectiveness of ALA-3000 for people with depression.
Who is behind this study?
The study sponsor is Alar Pharmaceuticals Inc.
Did this study involve medication?
Yes. The study involved medication, including ALA-3000, Placebo and escitalopram, sertraline, duloxetine or venlafaxine XR.
Who was this study for?
This study was for people with depression. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
